Ipilimumab Injection

💊 Yervoi 50 mg Detailed Description 🏷️ Generic Name: Ipilimumab 💉 Dosage Form: Sterile powder for intravenous infusion (vial) 💪 Strength: 50 mg per vial 🎯 Indications: Yervoi is primarily indicated for the treatment of: Unresectable or metastatic melanoma Advanced non-small cell lung cancer (NSCLC) in combination with other immunotherapies Renal cell carcinoma (advanced kidney cancer) Other malignancies in combination therapy as approved by regulatory authorities 🧬 Description: Yervoi (ipilimumab) is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte antigen-4 (CTLA-4), a receptor found on T cells. CTLA-4 functions as an immune checkpoint, downregulating immune responses. By blocking CTLA-4, ipilimumab enhances T-cell activation and proliferation, thereby boosting the body s immune response against tumor cells. ⚙️ Mechanism of Action: CTLA-4 is a negative regulator of T-cell immune activity. Ipilimumab binds to CTLA-4, preventing its interaction with ligands (CD80/CD86) on antigen-presenting cells. This blockade removes inhibitory signals and promotes sustained T-cell activation and proliferation, enabling the immune system to better recognize and attack cancer cells. 💉 Administration: Given as an intravenous infusion over approximately 90 minutes. Typical dosing is 3 mg/kg every 3 weeks for 4 doses. May be used alone or in combination with other immunotherapies like nivolumab. Treatment and dosing schedules may vary based on indication and patient response. Requires administration under the supervision of an experienced healthcare professional in a setting equipped to manage immune-related adverse events. ⚠️ Common Side Effects: Fatigue Diarrhea and colitis (inflammation of the colon) Rash, itching, and skin reactions Immune-related adverse events affecting organs such as liver (hepatitis), lungs (pneumonitis), endocrine glands (thyroiditis, hypophysitis), and others Nausea and vomiting Fever and chills Infusion-related reactions ❗ Warnings and Precautions: Immune-mediated adverse reactions can be severe and sometimes fatal. Early recognition and management with corticosteroids or immunosuppressants are critical. Patients should be monitored regularly for signs of inflammation or organ dysfunction. Use caution in patients with autoimmune diseases or pre-existing inflammatory conditions. 🏭 Manufacturer: Bristol-Myers Squibb

Melanoma: Treats skin cancer that has spread or cannot be removed by surgery, and helps prevent it from returning after surgery. Lung Cancer: Used with other drugs for non-small cell lung cancer.

Available ready stock

Yervoy 50mg/10mL is a premium, high-value antineoplastic human monoclonal antibody engineered for intravenous (IV) infusion. Classified as a pioneering cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking immune checkpoint inhibitor, it acts at the fundamental cellular level to unlock the body's natural immune response against advanced malignancies. Developed by global biopharmaceutical leader Bristol Myers Squibb (BMS), Yervoy is a frontline medical commodity heavily demanded by international cancer centers, hospital procurement networks, and global distributors.

Yervoy 50 Mg 10 Ml

Original, Delivery per patient to India or wholesale, Temperature controlled delivery.

IPILIMUMAB